Targeting Glutamine Utilization in Therapy-Resistant Prostate Cancer
Abstract
Prostate cancer (PCa) is the most common non-cutaneous cancer in men, leading to ~30,000 deaths annually in the US. Androgen deprivation therapy (ADT) remains the mainstay for patients with advanced and metastatic PCa. Although the treatment is efficacious initially, the disease will eventually recur as castration resistant PCa (CRPC). Second generation of hormonal therapy drugs, such as abiraterone and enzalutamide, are useful for CRPC but resistance eventually develops. Histologically, most cases relapse as adenocarcinoma, maintaining luminal differentiation including the expression of androgen receptor (AR) and prostate specific antigen (PSA). However, in up to 25% of the patients, the recurrent tumor after hormonal therapy shows neuroendocrine (NE) phenotype with suppressed AR signaling. Thus, developing therapeutic strategies independent of AR is a pressing unmet clinical need.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2022
- Accession Number
- AD1175563
Entities
People
- Jiaoti Huang
- Lingfan Xu
Organizations
- Duke University